CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited (CSPCY) Revenue
Annual & quarterly revenue history · segment & region breakdown
CSPCY · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsCSPC Pharmaceutical Group Limited trailing twelve-month (TTM) revenue is $44.14B, a decrease of 12.77% year-over-year from $25.29B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $25.29B | -$3.70B | -12.77% |
| 2024-12-31 | $28.99B | -$5.61B | -16.21% |
| 2023-12-31 | $34.60B | +$3.66B | +11.84% |
| 2022-12-31 | $30.94B | +$3.04B | +10.89% |
| 2021-12-31 | $27.90B | +$2.98B | +11.94% |
| 2020-12-31 | $24.92B | +$2.85B | +12.89% |
| 2019-12-31 | $22.08B | +$1.91B | +9.46% |
| 2018-12-31 | $20.17B | +$4.71B | +30.44% |
| 2017-12-31 | $15.46B | +$3.09B | +25.01% |
| 2016-12-31 | $12.37B | +$0.98B | +8.56% |
Compare revenue vs peers
Drug Manufacturers - GeneralCompare CSPCY revenue against listed peers. Click any row to open that company's revenue tab.
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income CSPC Pharmaceutical Group Limited receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
CSPC Pharmaceutical Group Limited reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CNY.
Data sourced from CSPC Pharmaceutical Group Limited's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CSPCY revenue · 4 questionsCSPCY's trailing twelve-month (TTM) revenue is $44.14B. That is a decrease of 12.77% year-over-year from $25.29B in FY2025.
▸ Source: FMP · CSPC Pharmaceutical Group Limited SEC filings · GAAP · CSPC Pharmaceutical Group Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026